gms | German Medical Science

83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2012, Mainz

Observation of the Effectiveness of Intranasal Budesonide Suspension Nebulization on Olfactory Disorders Associated with URTI or Nasal and Sinus Inflammatory

Meeting Abstract

Suche in Medline nach

  • corresponding author Daofeng Ni - Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peki, Beijing, P.R. China
  • Jing Guan - Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peki, Beijing, P.R. China
  • Jian Wang - Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peki, Beijing, P.R. China
  • Yingying Zhu - Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peki, Beijing, P.R. China

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Mainz, 16.-20.05.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12hnod663

doi: 10.3205/12hnod663, urn:nbn:de:0183-12hnod6639

Veröffentlicht: 4. April 2012

© 2012 Ni et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: To evaluate the effect of intranasal budesonide nebulization in 20 patients with olfactory disorders associated with upper respiratory tract infection (URTI) or nasal and nasal sinus inflammatory diseases.

Methods: We performed various tests on the 20 patients (9 males and 11 females; age range 18-63 years old) with olfactory loss induced by URTI,nasosinusitis, allergic rhinitis, or olfactory cleft disease. These tests or procedures include medical history collection, physical examination of the nose, head and neck, olfactory tests and medical imaging. Olfactory function was first assessed by T&T olfactometry and olfactory event-related potentials (OERPs) before budesonide treatment. This was done to evaluate the baseline olfactory function. Budesonide (1mg/2ml) was then administrated via an intranasal nebulization once daily for 15 days. T&T olfactometry was performed after every 5 treatments to determine the therapeutic value of budesonide nebulization. OERPs tests were repeated after the 15th treatment in 13 patients .

Results: In these 20 patients treated with budesonide nebulization, olfactory function was overall enhanced by 90%, that is, olfactory dysfunction was cured in 25%, improved in 50%, and slightly enhanced in 15% of the patients. We also observed that the treatment is the most effective after 10 nebulization treatments.

Conclusion: These results suggest that intranasal nebulization with budesonide may be an effective therapy for the treatment of URTI-related or nasal and nasal sinus inflammation-related olfactory disorders.